BioNTech, Fosun launch another COVID-19 vaccine trial

Credit: REUTERS/RALPH ORLOWSKI

Germany's BioNTech and China's Shanghai Fosun Pharmaceutical on Wednesday announced the start of another COVID-19 vaccine trial in China with a total of 144 participants.

BERLIN, Aug 5 (Reuters) - Germany's BioNTech BNTX.O and China's Shanghai Fosun Pharmaceutical 600196.SS on Wednesday announced the start of another COVID-19 vaccine trial in China with a total of 144 participants.

"The study is designed to support the regulatory approval process for the Chinese market and intends to confirm that the safety and immunogenicity profile observed in participants from the German and U.S. trials is comparable to that of Chinese participants," BioNTech said in a statement.

(Reporting by Thomas Seythal Editing by Michelle Martin)

((frankfurt.newsroom@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BNTX

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More